APLM
Apollomics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.50
−1.82%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
Market Cap
$79.64M
MomentumView details →
1D Return
−1.82%
YTD Return
+49.25%
RSI (14)
73.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
Market Cap
$79.64M
RSI (14)
73.0
MomentumView details →
1D Return
−1.82%
YTD Return
+49.25%
SummaryUpdated Dec 1, 2025
Apollomics, Inc. (NASDAQ:APLM) is a clinical-stage biotechnology company founded in 2015 and headquartered in Foster City, California. Originally incorporated as CBT Pharmaceuticals, Inc., the company changed its name to Apollomics in January 2019 and completed its transition to a publicly traded company on NASDAQ in March 2023. The company operates research and development facilities across California, China (Hangzhou and Shanghai), and Australia, focusing on the discovery and development of innovative oncology therapies to address significant unmet medical needs in cancer treatment.
Similar companies
Latest newsMore news →
Apollomics Inc. CFO Peter Kuan-How Lin purchased 26,667 Class A ordinary shares at $15.0 per share, totaling $400,005, on August 14, 2026, as part of a private placement.18d agoApollomics Inc. announced a private placement of securities to accredited investors for approximately $10 million, expected to close on August 14, 2026.24d agoApollomics Inc. received notice from Nasdaq that it regained compliance with the Market Value of Listed Securities requirement for continued listing on the Nasdaq Capital Market.53d ago